ArticleAnnals of medicine2025
Fibrinogen/albumin ratio is associated with first-ever cardiovascular events in patients with peritoneal dialysis.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Value of Fibrinogen-to-Albumin Ratio and Neutrophil-to-Lymphocyte Ratio in Patients on Peritoneal Dialysis.Life (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe fibrinogen/albumin ratio (FAR) is a novel inflammatory indicator, which has been associated with cardiovascular disease. However, the relationship between FAR and cardiovascular event (CVE) in patients with peritoneal dialysis (PD) remains unclear. This study aims to clarify the relationship between FAR and first-ever CVE in patients with PD.
methodsA total of 278 patients were enrolled between January 2012 and June 2021. They were defined as the high FAR group and the low FAR group based on the median FAR value (0.107). The primary outcome was the occurrence of first-ever CVE. Kaplan-Meier's curves and Cox regression analysis were used to analyse the relationship between FAR and first-ever CVE in patients with PD. Forest plots were employed to depict the relationship between FAR and first-ever CVE in each subgroup.
resultsThe average follow-up period was 40.26 ± 28.27 months. A total of 101 (36.3%) patients developed first-ever CVE. Kaplan-Meier's analysis showed that there was a higher risk of first-ever CVE (
conclusionsHigh levels of FAR are independently associated with an increased risk of first-ever CVE in patients with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.